City Therapeutics is targeting a valuation of up to $956.3 million in its United States initial public offering, aiming to raise up to $184.7 million. The offering comprises 9.7 million shares priced between $17 and $19 each.

The biotechnology sector continues its listing push despite market uncertainty and geopolitical tensions, following similar moves by peers like Retension Pharmaceuticals and TRex Bio. NVIDIA CORP-backed Iambic Therapeutics also launched its roadshow this week.